基于系统综述和Meta分析评价连花清瘟防治新冠肺炎的疗效及安全性

Xiao-hu SUN; Shuo ZHANG; Zhen YANG; Zhen-lin CHEN; Shi-jun YUE; Sai ZHANG; Yu-ping TANG

doi:10.1007/s11655-022-3578-8

Your Location：

Home >

Browse articles >

基于系统综述和Meta分析评价连花清瘟防治新冠肺炎的疗效及安全性

Evidence-Based Integrative Medicine | Updated：2022-06-27

- 基于系统综述和Meta分析评价连花清瘟防治新冠肺炎的疗效及安全性
- Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis
- Chinese Journal of Integrative Medicine 2022年28卷第7期页码：650-660
- Affiliations：
  
  1.Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for Traditional Chinese Medicine Compatibility,Shaanxi University of Chinese Medicine, Xi'an (712046), China
  2.Nanjing Bestform Pharmaceutical Technology Co., Ltd.,Nanjing (210032), China
  3.Cardiovascular Department,Guang'anmen Hospital, School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing (100029), China
  4.School of Public Health, Shaanxi University of Chinese Medicine, Xi'an (712046), China
  5.International Programs Office,Shaanxi University of Chinese Medicine, Xi'an (712046), China
- Author bio：
  
  Prof. TANG Yu-ping, E-mail: yupingtang@sntcm.edu.cn
- Funds：
  
  the Key Research and Development Program of Shaanxi(2019ZDLSF04-05);Subject Innovation Team of Shaanxi University of Chinese Medicine(2019-YL10)
- DOI：10.1007/s11655-022-3578-8
  中图分类号：
- 纸质出版日期：2022-07-01，
  
  录用日期：2022-03-30
Scan for full text
Xiao-hu SUN, Shuo ZHANG, Zhen YANG, 等. 基于系统综述和Meta分析评价连花清瘟防治新冠肺炎的疗效及安全性[J]. Chinese Journal of Integrative Medicine, 2022,28(7):650-660.

Xiao-hu SUN, Shuo ZHANG, Zhen YANG, et al. Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2022,28(7):650-660.
Xiao-hu SUN, Shuo ZHANG, Zhen YANG, 等. 基于系统综述和Meta分析评价连花清瘟防治新冠肺炎的疗效及安全性[J]. Chinese Journal of Integrative Medicine, 2022,28(7):650-660. DOI： 10.1007/s11655-022-3578-8.

Xiao-hu SUN, Shuo ZHANG, Zhen YANG, et al. Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2022,28(7):650-660. DOI： 10.1007/s11655-022-3578-8.

摘要

背景:

新冠肺炎 (COVID-19) 自暴发以来已在全球范围内传播

目前尚无确定的有效药物. 连花清瘟 (LHQW) 已在国内外广泛应用

在防治新冠肺炎方面具有一定优势.

目的:

运用系统评价和meta分析

评价LHQW防治COVID-19的疗效和安全性.

方法:

对12个电子数据库从建库至2021年10月30日的文献进行全面检索. 试验筛选采用Note Express 3.2.0

数据由2名研究人员独立提取一式两份. 采用Cochrane协作工具和Newcastle Ottawa量表评估随机对照试验和回顾性研究的偏倚风险

然后采用RevMan 5.3进行数据分析. 纳入使用LHQW防治COVID-19的随机对照试验或回顾性研究. 试验组干预措施为单独使用LHQW或联合使用化学药物 (LCWC)

对照组干预措施为化学药物 (CDs) . 观察指标包括计算机断层扫描 (CT) 恢复率、主要症状 (发热、咳嗽、乏力) 、呼吸系统、消化系统等症状消失率

疾病加重率和不良反应. 根据LHQW是否联合化学药物及对照组治疗方法的不同进行亚组分析.

结果:

9项试验包括1152名COVID-19参与者. LHQW和LCWC的CT恢复率分别为化学药物的1.36和1.32倍 (

0.05) . 与CDs相比

LCWC显著提高了发热、咳嗽、乏力、咳痰、气短、肌肉酸痛的消失率 (

0.05) . LHQW也能明显降低疾病加重率

是单用化学药物治疗的0.45倍 (

0.05) . 但LCWC与化学药物治疗相比

两组不良反应无统计学意义 (

0.05) .

结论:

LHQW更适合治疗有明显咳痰、气短、肌肉酸痛的COVID-19患者. LHQW防治COVID-19有一定优势

无明显的疾病加重. (PROSPERO注册号: CRD42021235937) .

Abstract

Background:

Corona virus disease 2019 (COVID-19) has spread around the world since its outbreak

and there is no ascertained effective drug up to now. Lianhua Qingwen (LHQW) has been widely used in China and overseas Chinese

which had some advantages in the treatment of COVID-19.

Objective:

To evaluate the efficacy and safety of LHQW for COVID-19 by conducting a systematic review with meta-analysis.

Methods:

A comprehensive literature search was conducted in 12 electronic databases from their establishment to October 30

2021. Note Express 3.2.0 was used for screening of trials

and the data was independently extracted in duplicate by 2 researchers. The risk of bias of randomized controlled trials (RCTs) and retrospective studies were assessed by using the Cochrane collaboration tool and Newcastle Ottawa Scale

respectively

followed by data analysis using RevMan 5.3. The RCTs or retrospective studies to treat COVID-19 using LHQW were included. The intervention measures in the experimental group were LHQW alone or combined with chemical drugs (LCWC)

and that in the control group were chemical drugs (CDs). Outcome measures included computed tomography (CT) recovery rate

disappearance rates of primary (fever

cough

fatigue)

respiratory

gastrointestinal and other symptoms

exacerbation rate and adverse reaction. Subgroup analysis was conducted according to whether LHQW was combined with CDs and the different treatment methods in the control group.

Results:

Nine trials with 1

152 participants with COVID-19 were included. The CT recovery rates of LHQW and LCWC were 1.36 and 1.32 times of CDs

respectively (

0.05). Compared with CDs

LCWC remarkably increased the disappearance rates of fever

cough

fatigue

expectoration

shortness of breath

and muscle soreness (

0.05). LHQW also obviously decreased the exacerbation rate

which was 0.45 times of CDs alone (

0.05). There was no obvious difference between LCWC and CDs in adverse reaction (

0.05).

Conclusions:

LHQW was more suitable for treating COVID-19 patients with obvious expectoration

shortness of breath and muscle soreness. LHQW had advantages in treating COVID-19 with no obvious exacerbation. (PROSPERO No. CRD42021235937)

关键词

Keywords

Lianhua QingwenCOVID-192019-nCoVsystematic reviewmeta-analysisChinese medicine

references

Chakraborty C, Sharma AR, Sharma G, Bhattacharya M,Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci 2020;24:4016-4026.

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.J Autoimmun 2020;109:102433.

National and Provincial Health Commissions. Real time big data report on the epidemic situation of COVID-19 pneumonia.Access on March 24, 2022. Available at https://voice.baidu.com/act/newpneumonia/newpneumonia/?from=osari_aladin_bannerhttps://voice.baidu.com/act/newpneumonia/newpneumonia/?from=osari_aladin_banner.

Wissem H, Nadia BL. COVID-19: main therapeutic options.Tunis Med 2020;98:299-303.

Duan ZP, Jia ZH, Zhang J, Liu S, Chen Y, Liang LC, et al.Natural herbal medicine Lianhuaqingwen Capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J 2011;124:2925-2933.

Yuan B. Chinese medicine, which targets body's response state, is an effective way to treat epidemic infectious diseases. Chin J Integr Med 2022;28:168-175.

Ji XY, Ma Y, Shi S, Liu SH, Tong L, Lu Cheng, et al.Medication rule analysis of the diagnosis and treatment programs of Chinese medicine for the prevention and treatment of COVID-19 in China. Chin J Integr Med 2022.[Epub ahead of print]

Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020;155:104743.

Liu M, Gao Y, Yuan Y, Yang KL, Shi SZ, Zhang JH, et al.Efficacy and safety of integrated traditional Chinese and Western medicine for corona virus disease 2019(COVID-19): a systematic review and meta-analysis.Pharmacol Res 2020;158:104896.

Zheng SC, Baak JP, Li S, Xiao WK, Ren H, Yang H, et al. Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in corona virus disease 2019 (COVID-19),gives fundamental support to the clinical use of LHQW.Phytomedicine 2020;79:153336.

National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of COVID-19 pneumonia. Access on March 4, 2020. Available at http://www.nhc.gov.cn/http://www.nhc.gov.cn/

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Meta Anal 2017;5:80-84.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;97:557-560.

Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ 2015;351:h4718.

Chen JJ, Zhou YL, Chen FG, Liu X, Chen YL,Wang S. Clinical study on treatment of COVID-19 in convalescent period treated with Lianhua Qingwen Capsule combined with interferon α-2b. Adv Clin Med(Chin) 2020;10:1144-1149.

Cheng DZ, Wang WJ, Li Y, Wu XD, Zhou B, Song QY.Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Tianjin J Tradit Chin Med (Chin) 2020;37:509-516.

Fang F, Yang L, Qin SC, Jiao R. Lianhua Qingwen Granule in the treatment of 42 children suspected cases of COVID-19. Chin New Drugs (Chin) 2020;29:2809-2812.

Hu K, Guan WJ, Bi Y, Zhang W, Li LJ, Zhang BL, et al.Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2020;85:153242.

Lv RB, Wang WJ, Li X. Clinical observation on Lianhua Qingwen Granules combined with Western medicine conventional therapy in the treatment of 63 suspected cases of coronavirus disease 2019. J Tradit Chin Med(Chin) 2020;61:655-659.

Xu XH, Dong H, Tu SH, Zhang MM, Liu D, Zhang HQ,et al. Retrospective analysis of Jinye Budu Granule and Lianhua Qinwen Capsule in the treatment of common type COVID-19. Res Integr Tradit Chin West Med (Chin)2020;12:383-386,389.

Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. Chin Exp Tradit Med Form (Chin) 2020;26:8-12.

Yu P, Li YZ, Wan SB, Wang Y. Effects of Lianhua Qingwen Granules plus arbidol on treatment of mild corona virus disease-19. Chin Pharm J (Chin) 2020;55:1042-1045.

Yu HY, Ren XH, Qi XX, Zuo Q, Liu D. Efficacy study of arbidol, Qingfei Paidu Decoction, Lianhua Qingwen Capsule and Jinye Baidu Granules in the treatment of mild/moderate COVID-19 in a Fangcang Shelter Hospital. Chin Assoc Chin Med (Chin) 2020;36:2-6.

Hu CY, Liang MM, Gong FF, He B, Zhao DD, Zhang GL.Efficacy of Lianhua Qingwen compared with conventional drugs in the treatment of common pneumonia and COVID-19 pneumonia: a meta-analysis. Evid Based Complement Alternat Med 2020;2020:5157089.

Liu M, Gao Y, Yuan Y, Yang KL, Shi SZ, Tian JH, et al.Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: a systematic review and meta-analysis.Integr Med Res 2021;10:100644.

Zeng MJ, Li LJ, Wu ZQ. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): meta-analysis of randomized controlled trials.PLoS One 2020;15:e0238828.

Li GD, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019nCoV). Nat Rev Drug Discov 2020;19:149-150.

Pan WQ, Li RF, Hou YL, Huang JC, Ma QH, Shi YX,et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARSCoV2). Pharmacol Res 2020;156:104761.

Wang SH, Liu JF, Zhang YL, Dong Z. Systematic review of efficacy and safety of Lianhua Qingwen Capsules in treatment of viral influenza. Chin J Chin Mater Med (Chin)2019;44:1503-1508.

Ding Y, Zeng L, Li R, Chen QY, Zhou BX, Chen OL,et al. The Chinese prescription Lianhuaqingwen Capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Alternat Med 2017;17:130.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Efficacy and Safety Evaluation of Taohong Siwu Decoction(桃红四物汤) for Patients with Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials

Clinical Practice Guidelines and Experts' Consensuses for Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Chinese Herbal Medicine: A Systematic Review

Blood-Letting Therapy for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Pregnancy Benefit of Acupuncture on in vitro Fertilization: A Systematic Review and Meta-Analysis

Effectiveness and Safety of Chinese Medicine at Shenque(CV 8) for Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials